Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
|Podcasts|April 9, 2022
Here's to a Psychedelic Revolution
Author(s)Amir Inamdar MBBS, DNB (Psych), MFPM
Research is underway to make psychedelics agents a treatment option for psychiatric disorders.
Advertisement
PSYCH PEARLS PODCAST
As part of a psychedelic revolution, careful research is underway to see how these compounds may benefit patients with psychiatric disorders. In this episode, Amir Inamdar MBBS, DNB (Psych), MFPM, shares insights and thoughts about the work being done and its potential to make a difference in patient care.
Advertisement
Related to this article
Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests
Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
2
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
3
FDA Shelves Fast-Track Drug Review Initiative
4
Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and Schizophrenia
5